Market Overview - The market experienced a decline following Fed Chair Jerome Powell's speech, which highlighted market uncertainty and stagflation [1] - Major indices closed lower, with the S&P 500 and Nasdaq both down 0.3%, the Dow Jones Industrial Average down 0.4%, and the Russell 2000 down 0.9% after reaching a 52-week high [2] Sector Performance - The oil and energy sectors emerged as the best performers, with the Energy Select Sector SPDR Fund (XLE) gaining 1.3% [2][7] - Gold prices dipped 1.5% after a rally, although analysts expect prices to continue climbing [3] Consumer Spending and Economic Indicators - A Bank of America report indicated that total debit and credit card spending per household has increased in recent months [4][7] - There was a reported surge in new house sales, but economists dismissed it as a fluke [4] Notable Stock Movements - Lithium Americas (LAC) saw a stock increase of 95.5%, while Tesla gained 4% due to analyst confidence [4] - uniQure, a gene therapy company, experienced a significant stock surge of 247.8% following positive results from its AMT-130 study for Huntington's disease [10] Noteworthy Stocks - Stocks with notable gains included Xcel Energy Inc (+6.7%), Intel Corp (+6.4%), Centene Corp (+5.8%), Mosaic Co (+4.3%), and CF Industries Holdings Inc (+5.7%) [8] - Conversely, the worst-performing stocks included Freeport-McMoRan Inc (-16.9%), Axon Enterprise Inc (-10.2%), and KKR & Co Inc (-6.3%) [12]

Core Insights - Several companies and ETFs have experienced significant gains in trading, attracting investor attention [1] Company Performance - uniQure N.V. (QURE) saw its stock price rise to $45.1, an increase of $31.44 or approximately 230.16%, reaching a new year high of $51.19 from a low of $4.45, with a trading volume of 58,563,496 shares [2] - SHF Holdings, Inc. (SHFS) had its stock price jump to $7.01, up by $3.75 or 115.03%, with a day high of $9.18 and a trading volume of 29,808,900 shares [3] ETF Performance - ETFs from Nushares ETF Trust, including Nuveen High Yield Corporate Bond ETF (NHYB), Securitized Income ETF (NSCI), and Nuveen International Aggregate Bond ETF (NXUS), each experienced a 100% increase in their prices, reaching $25.01, $25.03, and $25.02 respectively [4] Market Dynamics - The market movements highlight the volatility in valuations driven by factors such as clinical trial results, regulatory approvals, and market sentiment [5]

Core Insights - ClearPoint Neuro's medical device is significant in UniQure's strategy to combat Huntington's disease [1] Company Summary - ClearPoint Neuro provides a medical device that is integral to the treatment efforts for Huntington's disease by UniQure [1] - UniQure is leveraging ClearPoint Neuro's technology to enhance its capabilities in addressing Huntington's disease [1]

Group 1 - The article discusses the investment analysis service provided by Biotech Analysis Central, which focuses on pharmaceutical companies and offers a subscription model for in-depth research [1][2] - The service includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis tools to assist healthcare investors [2] - A previous article on uniQure N.V. highlighted the progress of AMT-130 for Huntington's Disease, with an upcoming FDA meeting scheduled for Q2 2025 [2]

Group 1 - The article discusses the investment analysis service provided by Biotech Analysis Central, which focuses on pharmaceutical companies and offers a subscription model for in-depth research [1][2]. - The service includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis tools to assist healthcare investors [2]. - A previous article on uniQure N.V. highlighted the progress of AMT-130 for Huntington's Disease, with an upcoming FDA meeting scheduled for Q2 2025 [2].

Skip to Main Content This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. These Stocks Moved the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More By Joe Woelfel, Elsa Ohlen, Mackenzie Tatananni and Connor Smith Share Resize Reprints Continue ...

Core Viewpoint - Orsted has resumed work on a U.S. offshore wind project following a federal judge's ruling that allows construction to restart amid ongoing legal challenges from the Trump administration [1] Group 1 - Orsted is a key player in the offshore wind industry, and the resumption of construction indicates a positive development for renewable energy projects in the U.S. [1] - The federal judge's ruling is significant as it provides a legal pathway for Orsted to continue its operations despite the ongoing legal case [1]

Core Viewpoint - uniQure N.V. has initiated a $200 million underwritten public offering of its ordinary shares and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% of the total shares sold [1][2]. Company Overview - uniQure is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs, including gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, and Fabry disease [5]. - The company has achieved significant milestones in genomic medicine, particularly with its gene therapy for hemophilia B, which is based on over a decade of research and clinical development [5]. Offering Details - The public offering is subject to market conditions, and there is no assurance regarding its completion or the final terms [1]. - The offering is being conducted under an automatically effective shelf registration statement filed with the SEC [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]. Underwriters - The bookrunning managers for the offering include Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities [2].

Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease. Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well. More News from Barchart QURE stock is now trading roughly 460% above its year-to-date low in early April. www.barchart.com Why Did the Clinical Data Light a Fire Under QURE Stock? Uniqure shares are rall ...

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]